Neuraxon, Inc.

Ketogen Inc.

John S Andrews

Shawn Maddaford

Subhash Annedi

Suman Rakhit

Paul Renton

Jailall Ramnauth

Joanne Patman

Peter Dove

Jaipal Reddy Nagireddy

Joseph A Araujo

Guy A Higgins

Sarah Silverman

Norton W Milgram

Paula J Estey

Gary L W G Robinson

Gabriela Mladenova

Subhash C Annedi

Gary Lwg Robinson

Jaipal R Nagireddy

The present application relates to novel compounds comprising a moiety that leads to the metabolic production of ketones bonded to a ketone-potentiated anti-epileptic drug, compositions comprising these compounds, and their use, for example for the treatment of epilepsy, and other CNS diseases, disorders or conditions. In particular, the present application includes compounds of Formula I, and compositions and uses thereof: 

Compounds for the treatment of seizures and other central nervous systems disorders and conditions

The invention features methods of treating visceral pain or a condition in a mammal caused by the action of nitric oxide synthase (NOS) or by the action of serotonin 5HT1D/1B receptors, by administering to a patient in need thereof a therapeutically effective amount of an indole compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof. The methods of the invention may further comprise the administration of additional therapeutic agent. The invention also features new compounds of Formula (I), pharmaceutical compositions thereof, and methods of resolving enantiomeric mixtures.

Indole compounds and methods for treating visceral pain

The present invention features quinolones, tetrahydroquinolines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.

Quinolone and tetrahydroquinolone and related compounds having NOS inhibitory activity

The present invention relates to benzimidazole compounds having dual nitric oxide synthase (NOS) inhibitory activity and agonist activity at the mu-opioid receptor, to pharmaceutical and diagnostic compositions containing them, and to their medical use, particularly as compounds for the treatment or prevention of chronic pain, acute pain, migraine, and neuropathic pain.

Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity

Growing community of inventors

Mississauga, Canada

John S Andrews